Skip to main content

Advertisement

SpringerLink
Log in

Assessment of circulating HISLA as a potential biomarker for breast cancer diagnosis and prognosis

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Breast cancer (BC) is the most frequently encountered and aggressive type of malignant tumor and affects the health of females across the globe. Approximately 30% of patients that are newly diagnosed have a high risk of subsequent metastasis and relapse. HIF-1α-stabilizing long noncoding RNA (HISLA) packaged in exosome has been recently identified and revealed as an important oncogenic gene in promoting BC progress. Thus, we sought to investigate whether serum circulating HISLA was involved in dynamics underlying its applicability for the diagnosis and prognosis of BC. We assessed serum HISLA expression in 40 patients with BC and 20 healthy controls to investigate its roles in BC using quantitative real-time polymerase chain reaction (qRT-PCR). We also assessed measures of correlation of clinical and pathological parameters with prognoses of BC patients. Our findings suggested that serum HISLA expression in BC patients was significantly higher than in healthy controls. Furthermore, high expression of serum HISLA was positively associated with advanced stage lymph node metastasis. Expression of HISLA was reduced in postoperative BC patients’ serum samples, compared with preoperative serum samples. Pearson correlation assessments indicated significant correlation between serum HISLA expression and the tissue sample HISLA expression in BC patients. Our findings suggested that serum HISLA may serve as newfound biomarker which could help to improve diagnoses and prognoses for BC-afflicted patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  Google Scholar 

  2. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–48.

    Article  Google Scholar 

  3. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol. 2010;28(11):1958–62.

    Article  Google Scholar 

  4. Cote B, Rao D, Alany RG, Kwon GS, Alani AWG. Lymphatic changes in cancer and drug delivery to the lymphatics in solid tumors. Adv Drug Deliv Rev. 2019;144:16–34.

    Article  CAS  Google Scholar 

  5. Karaman S, Detmar M. Mechanisms of lymphatic metastasis. J Clin Invest. 2014;124(3):922–8.

    Article  CAS  Google Scholar 

  6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.

    Article  Google Scholar 

  7. Babyshkina N, Vtorushin S, Dronova T, et al. Impact of estrogen receptor alpha on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer. Clin Exp Med. 2019;19(4):547–56.

    Article  Google Scholar 

  8. Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21(11):1253–61.

    Article  CAS  Google Scholar 

  9. Yao RW, Wang Y, Chen LL. Cellular functions of long noncoding RNAs. Nat Cell Biol. 2019;21(5):542–51.

    Article  CAS  Google Scholar 

  10. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013;14(11):699–712.

    Article  CAS  Google Scholar 

  11. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. Cancer Discov. 2011;1(5):391–407.

    Article  CAS  Google Scholar 

  12. Liu B, Sun L, Liu Q, et al. A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015;27(3):370–81.

    Article  CAS  Google Scholar 

  13. Wang W, He X, Zheng Z, et al. Serum HOTAIR as a novel diagnostic biomarker for esophageal squamous cell carcinoma. Mol Cancer. 2017;16(1):75.

    Article  CAS  Google Scholar 

  14. Tan SK, Pastori C, Penas C, et al. Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme. Mol Cancer. 2018;17(1):74.

    Article  Google Scholar 

  15. Chen F, Chen J, Yang L, et al. Extracellular vesicle-packaged HIF-1alpha-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells. Nat Cell Biol. 2019;21(4):498–510.

    Article  CAS  Google Scholar 

  16. Morrow M. Management of the node-positive axilla in breast cancer in 2017: selecting the right option. JAMA Oncol. 2018;4(2):250–1.

    Article  Google Scholar 

  17. Santa-Maria CA, Gradishar WJ. Changing treatment paradigms in metastatic breast cancer: lessons learned. JAMA Oncol. 2015;1(4):528–34 ((quiz 549)).

    Article  Google Scholar 

  18. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.

    Article  Google Scholar 

  19. Chen W. Cancer statistics: updated cancer burden in China. Chin J Cancer Res. 2015;27(1):1.

    PubMed  PubMed Central  Google Scholar 

  20. Brooks MD, Burness ML, Wicha MS. Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell. 2015;17(3):260–71.

    Article  CAS  Google Scholar 

  21. Arnedos M, Vicier C, Loi S, et al. Precision medicine for metastatic breast cancer—limitations and solutions. Nat Rev Clin Oncol. 2015;12(12):693–704.

    Article  CAS  Google Scholar 

  22. Curigliano G, Criscitiello C. Maximizing the clinical benefit of anthracyclines in addition to taxanes in the adjuvant treatment of early breast cancer. J Clin Oncol. 2017;35(23):2600–3.

    Article  CAS  Google Scholar 

  23. Zhang X, Ju S, Wang X, Cong H. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer. Clin Exp Med. 2019;19(3):271–9.

    Article  CAS  Google Scholar 

  24. Avalos-Navarro G, Munoz-Valle JF, Daneri-Navarro A, et al. Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with Th17 cytokine profile. Clin Exp Med. 2019;19(3):385–91.

    Article  CAS  Google Scholar 

  25. Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172(3):393–407.

    Article  CAS  Google Scholar 

  26. Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19(3):143–57.

    Article  CAS  Google Scholar 

  27. Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer. 2020;19(1):77.

    Article  CAS  Google Scholar 

  28. Cheng J, Meng J, Zhu L, Peng Y. Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications. Mol Cancer. 2020;19(1):66.

    Article  CAS  Google Scholar 

  29. Ramnarine VR, Kobelev M, Gibb EA, et al. The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management. Eur Urol. 2019;76(5):546–59.

    Article  CAS  Google Scholar 

  30. Yuan L, Xu ZY, Ruan SM, Mo S, Qin JJ, Cheng XD. Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance. Mol Cancer. 2020;19(1):96.

    Article  Google Scholar 

  31. Guo X, Lv X, Ru Y, et al. Circulating Exosomal Gastric cancer-associated long noncoding RNA1 as a biomarker for early detection and monitoring progression of gastric cancer: a multiphase study. JAMA Surg. 2020;155(7):572–9.

    Article  Google Scholar 

  32. Qi P, Zhou XY, Du X. Circulating long non-coding RNAs in cancer: current status and future perspectives. Mol Cancer. 2016;15(1):39.

    Article  Google Scholar 

  33. Lin LY, Yang L, Zeng Q, et al. Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer. Mol Cancer. 2018;17(1):84.

    Article  Google Scholar 

Download references

Funding

This study was supported by the Shenzhen People’s Hospital Cultivating Funding Project from Shenzhen Municipal Health Commission (No. SYLY201704).

Author information

Authors and Affiliations

  1. Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China

    Hong Hu & Changsheng Ye

  2. Department of Breast and Thyroid Surgery, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University, Shenzhen People’s Hospital, Shenzhen, 518020, China

    Hong Hu, Yipeng Yang & Wenbin Zhou

  3. Department of Pathology, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University, Shenzhen People’s Hospital, Shenzhen, 518020, China

    Jintao Hu

Authors
  1. Hong Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jintao Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yipeng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenbin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Changsheng Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CY conceived and designed the project; HH performed the experiment; JH collected the clinical samples and analysis; YY data statistical analysis; HH and WZ wrote the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Hong Hu or Changsheng Ye.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

This study was approved by the Ethics Committee of The Shenzhen People’s Hospital, and all of the participants provided informed consent.

Consent for publication

Written informed consent for publication was obtained from each participant.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, H., Hu, J., Yang, Y. et al. Assessment of circulating HISLA as a potential biomarker for breast cancer diagnosis and prognosis. Clin Exp Med 21, 29–34 (2021). https://doi.org/10.1007/s10238-020-00670-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-020-00670-z

Keywords

Search

Navigation